Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-arm Pilot Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Localized, HER2-negative, BRCA-mutant Breast Cancer Patients

NCT03329937 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT03329937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03329937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-arm Pilot Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Localized, HER2-negative, BRCA-mutant Breast Cancer Patients
Lead sponsor
Tesaro, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 12, 2018
Completion date
March 31, 2020
Enrollment
21 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, breast